Marker Therapeutics, Inc. (MRKR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MRKR Revenue Growth
Revenue Breakdown (FY 2025)
MRKR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MRKR Revenue Analysis (2014–2025)
As of May 8, 2026, Marker Therapeutics, Inc. (MRKR) generated trailing twelve-month (TTM) revenue of $3.5 million, reflecting significant decline in growth of -51.0% year-over-year. The most recent quarter (Q4 2025) recorded $1.1 million in revenue, down 10.5% sequentially.
Looking at the longer-term picture, MRKR's 5-year compound annual growth rate (CAGR) stands at +50.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $6.6 million in 2024.
Revenue diversification analysis shows MRKR's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FATE (-51.2% YoY), AGEN (+10.4% YoY), and ADCT (+4.4% YoY), MRKR has underperformed the peer group in terms of revenue growth. Compare MRKR vs FATE →
MRKR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MRKRCurrent | $4M | -51.0% | +50.0% | -350.7% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 ADCT | $81M | +4.4% | - | -133.2% |
MRKR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.5M | -46.2% | $0 | - | $-12,437,291 | -350.7% |
| 2024 | $6.6M | +99.1% | $-6,876,765 | -104.3% | $-11,118,372 | -168.7% |
| 2023 | $3.3M | -5.8% | $-7,105,656 | -214.6% | $-14,581,378 | -440.4% |
| 2022 | $3.5M | +183.0% | $-8,454,884 | -240.6% | $-19,791,004 | -563.3% |
| 2021 | $1.2M | +166.0% | $-1,920,928 | -154.7% | $-39,477,995 | -3179.3% |
| 2020 | $467K | +118.9% | $-18,414,000 | -3944.9% | $-28,886,000 | -6188.3% |
| 2019 | $213K | +3.5% | $-12,551,610 | -5887.4% | $-22,528,806 | -10567.3% |
| 2018 | $206K | +12.5% | $-123,792,000 | -60095.0% | $-148,172,000 | -71930.3% |
| 2017 | $183K | - | $-5,068,000 | -2768.4% | $-11,480,000 | -6271.0% |
| 2016 | $0 | - | $0 | - | $-8,492,000 | - |
See MRKR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRKR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRKR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRKR — Frequently Asked Questions
Quick answers to the most common questions about buying MRKR stock.
Is MRKR's revenue growth accelerating or slowing?
MRKR revenue declined -51.0% year-over-year, contrasting with the 5-year CAGR of +50.0%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is MRKR's long-term revenue growth rate?
Marker Therapeutics, Inc.'s 5-year revenue CAGR of +50.0% reflects the variable expansion pattern. Current YoY growth of -51.0% is below this long-term average.
How is MRKR's revenue distributed by segment?
MRKR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.